Psychopharmacology of hypnotics

Klinik Psikofarmakoloji Bulteni

Volumn 11, Issue 2, 2001, Pages 124-131

  Bourin, Michel ^a   Dhonnehadha, Bríd Áine Nic ^b  

^a UNIVERSITÉ DE NANTES   (France)

^b NONE

Author keywords

Benzodiazepines; Hypnotics; Hypnotics non benzodiazepines; Insomnia

Indexed keywords

EID: 1542777798     PISSN: 10177833     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Wagner J, Wagner ML, Hening WA. Beyond benzodiazepines: alternative pharmacologic agents for the treatment of insomnia. Ann Pharmacother 1998; 32:680-91.
2. Kupfer DJ, Reynolds III CF. Management of insomnia. M Engl J Med 1997; 336:341-6.
3. Roth T. Overview of insomnia for the primary care physician. In: Roberts WO, editor. Insomnia: treatment options for the 21st century. Minneapolis (MN):McGraw-Hill Healthcare Information Group. 2000:5-13.
4. Dement W. Sleep disorders and their substrates. Nouv Presse Med 1982; 11:2967-2980.
5. Mitler MM. Nonseletive and selective benzodiazepine receptor agonists-where are we today? Sleep 2000; 23 (Suppl 1):S39-47.
6. Richard P, Mark D, Deligne P. Competition pharmacologie entre les benzodiazepines, mise en evidence chez l'homme entre le diazepam et le flunitrazepam. Ann Anesthesiol Fr. 1981; 22:191-203.
7. Evans JL, Lewis SA. Drug withdrawal state. An EEG sleep study. Arch Gen Psychiat 1968; 19:631-634.
8. Boulenger JP, Patel J., Marangos P.J. Effects of caffeine and theophylline on adenosine and benzodiazepine receptors in human brain. Neurosci Lett 1982; 30:161-166.
9. Doghramji K. The need for flexibility in dosing of hypnotic agents. Sleep 2000 23 (Suppl 1):S16-20;discussioon S21-2.
10. Dooley M, Plosker GL. Zaleplon: a review of its use in the treatment of insomnia. Drugs 2000; 60:413-45
11. Bourin M, Bradwejn J. The importance of pharmacokinetic in prescribing benzodiazepines. In Pharmacocinétique: de la recherche à la clinique. Ed. J. Brès, G. Panis, John Libbey Euro text 1992:99-112.
12. Amrein R., Eckert M., Hafeli H., Leisham. Pharmacokinetic and clinical consideration in the choice of a hypnotic. Br J Clin Pharmacol 1983; 16:55-105.
13. Bourin M, Couëtoux du Tertre A, Payeur R. Evaluation of safety and side effects in the process of anti-anxiety drug development. Eur Psychiatry 1993; 8:285-291.
14. Morgan K, Tomeny M. Benzodiazepine withdrawal and rebound insomnia. Acta Psychiatr Scand 1989; 80:297-298.
15. Bixler EO, Scharf MB, Soldatos CR. Effects of hypnotic drugs on memory. Life Sci 1979; 25:1379-1388.
16. Liljequist R, Mattila MJ. Acute effects of temazepam and nitrazepam on psychomotor skills and memory. Acta Pharmacol Toxicol 1979; 44:364-369.
17. Liljequist R, Palva E, Linnoila M. Effects on learning and memory of 2-week treatments with chlordiazepoxide lactam-N-demethyldiazepam, oxazepam and methylloxazepam alone or in combination with alcohol. Int Pharmacopsychiat 1979; 14:190.
18. Poitras R. A propos d'épisodes d'amnésies antérogrades associées à l'utilisation du triazolam. Union Med Can 1980; 109:427-429.
19. Roth T, Hartse KM, Saab PG, Piccione PM, Kramer M. The effects of flurazepam, lorazepam and triazolam on sleep memory. Psychopharmacology 1980; 70:231-237.
20. Dundee IW, Mc Gowan Waw, Lilburn AC, Hegarty JE. Comparison of the actions of diazepam and lorazepam. Br J Anaesth 1979; 51:439-446.
21. Gallon S, Gale GD, Lancee WJ. Comparison of lorazepam and diazepam as premedicaments. Br J Anaesth 1977; 49:1265-1268.
22. Goa KL, Heel RC. Zopiclone: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy as an hypnotic. Drugs 1986; 32:48-65.
23. Leonard BE. Drug treatment of insomnia. In: Fundamentals of psychopharmacology.2nd edition. John Wiley & Sons Ltd. 1997:173-184.
24. Lader MH. Limitations on the use of benzodiazepines in anxiety and insomnia: are they justified? Eur Neuropsychopharmacol 1999;9(Suppl 6):S399-405.
25. Gaillot J, Heusse D, Houghton G, Aurele JM, Dreyfus J. Pharmacokinetics and metabolism of zopiclone. Pharmacology 1983; 27 (suppl 2):76-91.
26. Morgan K. Hypnotics in the elderly. What cause for concern? Drugs 1990; 40:688-696.
27. Nicholson AN, Pascoe PA. Hypnotic activity of an imidazopyridine (zolpidem). Br J Clin Pharmac 1986; 21:205-211.
28. Holm KJ, Goa KL. Zolipdem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia. Drugs 2000; 59:865-89.
29. Rosen AS, Fournié P, Darwish M, Danjou P, Troy SM. Zaleplon pharmacokinetics and absolute bioavailability. Biopharm Drug Dispos 1999; 20:171-5.
30. Darwish M. The effects of age and gender on the pharmacokinetics of zaleplon.(abstract) Eur Neuropsychopharmacol 1999; 9(Suppl 5):S360.
31. Wagner ML. Zaleplon CNS Drugs 1999; 2é(Suppl 2):S354-8.
32. Ancoli-Israel S. Insomnia in the elderly: a review for the primary care practitioner. Sleep 2000 2″ (Suppl 1) S23-30; discussion S36-8.
33. Weedle PB, Poston JW, Parish PA. Use of hypnotic medicines by elderly people in residential homes. J R Coll Gen Pract 1988; 38:156-158.